beta

ANIP

ANI Pharmaceuticals Inc.

Anip

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

11-06-2018 08-07-2018 05-08-2018 02-27-2018 11-02-2017 08-03-2017 05-04-2017
Actual EPS 1.17 1.01 1.23 1.0 1.03 0.88 0.62
Consensus EPS 1.1 1.21 1.1 1.02 0.9 0.79 0.7
Estimated EPS 1.1 1.21 1.1 1.02 0.9 0.79 0.7
Number of Estimates 1 1 1 2 2 2 2
EPS Surprise $0.07 -$0.20 $0.13 -$0.02 $0.13 $0.09 -$0.08

Stats

Summary

ANI Pharmaceuticals Inc is a specialty pharmaceutical company. The Company, together with its subsidiary is engaged in developing, manufacturing, and marketing branded and generic prescription pharmaceuticals.

Market Cap: 792 Million

Primary Exchange: NASDAQ Global Market

Website: http://www.anipharmaceuticals.com

Shares Outstanding: 11.7 Million

Float: 10.3 Million

Dividend: 0.0 (0.0%)

Beta: 2.767954

Sector: Healthcare

Industry: Biotechnology

Short Interest (Jan 12, 2018): 731 Thousand

Ethical Flags

Animal testing

Longest drawdown: 653 trading days

From: 2015-04-23 To: 2017-11-22

Lowest Point:

Generics under pressure on expanded price-fixing investigation

via: SeekingAlpha at 2018-12-10 12:53:46:000

The broad market's bearishness notwithstanding, generic drug makers are predominantly in the red on the news that the investigation into alleged price-fixing by state AGs now totals 47. More news on: Aceto Corporation, Aclaris Therapeutics, Akorn, Inc., Healthcare stocks news, Stocks on th… read more...

Generics under pressure on expanded price-fixing investigation

via: SeekingAlpha at 2018-12-10 12:53:46:000

The broad market's bearishness notwithstanding, generic drug makers are predominantly in the red on the news that the investigation into alleged price-fixing by state AGs now totals 47. More news on: Aceto Corporation, Aclaris Therapeutics, Akorn, Inc., Healthcare stocks news, Stocks on th… read more...

ANI Pharmaceuticals enters into separate agreements convertible notes holders

via: SeekingAlpha at 2018-12-07 08:26:33:000

ANI Pharmaceuticals (NASDAQ: ANIP ) has entered into separate, privately negotiated agreements with certain holders of its outstanding 3.00% Convertible Senior Notes due 2019. More news on: ANI Pharmaceuticals, Inc., Healthcare stocks news, Read more … read more...

ANI Pharmaceuticals enters into separate agreements convertible notes holders

via: SeekingAlpha at 2018-12-07 08:26:33:000

ANI Pharmaceuticals (NASDAQ: ANIP ) has entered into separate, privately negotiated agreements with certain holders of its outstanding 3.00% Convertible Senior Notes due 2019. More news on: ANI Pharmaceuticals, Inc., Healthcare stocks news, Read more … read more...

ANI Pharmaceuticals enters into separate agreements convertible notes holders

via: SeekingAlpha at 2018-12-07 08:26:33:000

ANI Pharmaceuticals (NASDAQ: ANIP ) has entered into separate, privately negotiated agreements with certain holders of its outstanding 3.00% Convertible Senior Notes due 2019. More news on: ANI Pharmaceuticals, Inc., Healthcare stocks news, Read more … read more...

ANI Pharmaceuticals Enters into Separate Privately Negotiated Agreements with Certain Holders of its Convertible Notes

via: PR Newswire at 2018-12-07 08:00:00:000

BAUDETTE, Minn. , Dec. 7, 2018 /PRNewswire/ --(NASDAQ: ANIP) ANI Pharmaceuticals, Inc. (the "Company" or "ANI") today announced that it has entered into separate, privately negotiated agreements with certain holders of its outstanding 3.00% Convertible Senior Notes due 2019 (the "No… read more...

ANI Pharmaceuticals Enters into Separate Privately Negotiated Agreements with Certain Holders of its Convertible Notes

via: PR Newswire at 2018-12-07 08:00:00:000

BAUDETTE, Minn. , Dec. 7, 2018 /PRNewswire/ --(NASDAQ: ANIP) ANI Pharmaceuticals, Inc. (the "Company" or "ANI") today announced that it has entered into separate, privately negotiated agreements with certain holders of its outstanding 3.00% Convertible Senior Notes due 2019 (the "No… read more...

ANI Pharmaceuticals Enters into Separate Privately Negotiated Agreements with Certain Holders of its Convertible Notes

via: PR Newswire at 2018-12-07 08:00:00:000

BAUDETTE, Minn. , Dec. 7, 2018 /PRNewswire/ --(NASDAQ: ANIP) ANI Pharmaceuticals, Inc. (the "Company" or "ANI") today announced that it has entered into separate, privately negotiated agreements with certain holders of its outstanding 3.00% Convertible Senior Notes due 2019 (the "No… read more...

ANI Pharmaceuticals, Inc. Ranked Number 366 Fastest Growing Company in North America on Deloitte's 2018 Technology Fast 500(TM)

via: PR Newswire at 2018-11-15 09:15:00:000

BAUDETTE, Minn. , Nov. 15, 2018 /PRNewswire/ --ANI Pharmaceuticals, Inc. ("ANI") (NASDAQ: ANIP) today announced it ranked No. 366 on Deloitte's Technology Fast 500, a ranking of the 500 fastest growing technology, media, telecommunications, life sciences and energy tech comp… read more...

ANI Pharmaceuticals, Inc. Ranked Number 366 Fastest Growing Company in North America on Deloitte's 2018 Technology Fast 500(TM)

via: PR Newswire at 2018-11-15 09:15:00:000

BAUDETTE, Minn. , Nov. 15, 2018 /PRNewswire/ --ANI Pharmaceuticals, Inc. ("ANI") (NASDAQ: ANIP) today announced it ranked No. 366 on Deloitte's Technology Fast 500, a ranking of the 500 fastest growing technology, media, telecommunications, life sciences and energy tech comp… read more...

ANI Pharmaceuticals, Inc. Ranked Number 366 Fastest Growing Company in North America on Deloitte's 2018 Technology Fast 500(TM)

via: PR Newswire at 2018-11-15 09:15:00:000

BAUDETTE, Minn. , Nov. 15, 2018 /PRNewswire/ --ANI Pharmaceuticals, Inc. ("ANI") (NASDAQ: ANIP) today announced it ranked No. 366 on Deloitte's Technology Fast 500, a ranking of the 500 fastest growing technology, media, telecommunications, life sciences and energy tech comp… read more...

Express Scripts launches new formulary aimed at reducing drug costs

via: SeekingAlpha at 2018-11-13 09:43:56:000

Express Scripts (NASDAQ: ESRX ) introduces its National Preferred Flex Formulary covering more than 3,800 branded and generic medicines. More news on: Express Scripts, Inc., Bausch Health Companies Inc., Roche Holding Ltd ADR, Healthcare stocks news, Read more … read more...

Express Scripts launches new formulary aimed at reducing drug costs

via: SeekingAlpha at 2018-11-13 09:43:56:000

Express Scripts (NASDAQ: ESRX ) introduces its National Preferred Flex Formulary covering more than 3,800 branded and generic medicines. More news on: Express Scripts, Inc., Bausch Health Companies Inc., Roche Holding Ltd ADR, Healthcare stocks news, Read more … read more...

ANI Pharmaceuticals, Inc. (ANIP) CEO Arthur Przybyl on Q3 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-11-06 15:54:10:000

ANI Pharmaceuticals, Inc. (ANIP) Q3 2018 Earnings Conference Call November 6, 2018 10:30 AM ET Executives Arthur Przybyl - President and Chief Executive Officer Stephen Carey - Vice President and Chief Financial Officer Analysts Brandon Folkes - Cantor Fitzgerald Elliot Wil… read more...

ANI Pharmaceuticals, Inc. (ANIP) CEO Arthur Przybyl on Q3 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-11-06 15:54:10:000

ANI Pharmaceuticals, Inc. (ANIP) Q3 2018 Earnings Conference Call November 6, 2018 10:30 AM ET Executives Arthur Przybyl - President and Chief Executive Officer Stephen Carey - Vice President and Chief Financial Officer Analysts Brandon Folkes - Cantor Fitzgerald Elliot Wil… read more...

ANI Pharmaceuticals, Inc. (ANIP) CEO Arthur Przybyl on Q3 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-11-06 15:54:10:000

ANI Pharmaceuticals, Inc. (ANIP) Q3 2018 Earnings Conference Call November 6, 2018 10:30 AM ET Executives Arthur Przybyl - President and Chief Executive Officer Stephen Carey - Vice President and Chief Financial Officer Analysts Brandon Folkes - Cantor Fitzgerald Elliot Wil… read more...

ANI Pharmaceuticals beats by $0.12, misses on revenue

via: SeekingAlpha at 2018-11-06 08:31:38:000

ANI Pharmaceuticals (NASDAQ: ANIP ): Q3 Non-GAAP EPS of $1.29 beats by $0.12 ; GAAP EPS of $0.42 misses by $0.04 . More news on: ANI Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...

ANI Pharmaceuticals beats by $0.12, misses on revenue

via: SeekingAlpha at 2018-11-06 08:31:38:000

ANI Pharmaceuticals (NASDAQ: ANIP ): Q3 Non-GAAP EPS of $1.29 beats by $0.12 ; GAAP EPS of $0.42 misses by $0.04 . More news on: ANI Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...

ANI Pharmaceuticals beats by $0.12, misses on revenue

via: SeekingAlpha at 2018-11-06 08:31:38:000

ANI Pharmaceuticals (NASDAQ: ANIP ): Q3 Non-GAAP EPS of $1.29 beats by $0.12 ; GAAP EPS of $0.42 misses by $0.04 . More news on: ANI Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...

ANI Pharmaceuticals Reports Third Quarter and Year-To-Date 2018 Results and Reaffirms Guidance

via: PR Newswire at 2018-11-06 08:30:00:000

BAUDETTE, Minn. , Nov. 6, 2018 /PRNewswire/ -- For the third quarter 2018: Record net revenues of $50.7 million , an increase of 5% as compared to the same period in 2017 GAAP net income of $5.0 million and diluted GAAP earnings per share of $0.42 Adjusted non-GAAP E… read more...

ANI Pharmaceuticals Reports Third Quarter and Year-To-Date 2018 Results and Reaffirms Guidance

via: PR Newswire at 2018-11-06 08:30:00:000

BAUDETTE, Minn. , Nov. 6, 2018 /PRNewswire/ -- For the third quarter 2018: Record net revenues of $50.7 million , an increase of 5% as compared to the same period in 2017 GAAP net income of $5.0 million and diluted GAAP earnings per share of $0.42 Adjusted non-GAAP E… read more...

ANI Pharmaceuticals Reports Third Quarter and Year-To-Date 2018 Results and Reaffirms Guidance

via: PR Newswire at 2018-11-06 08:30:00:000

BAUDETTE, Minn. , Nov. 6, 2018 /PRNewswire/ -- For the third quarter 2018: Record net revenues of $50.7 million , an increase of 5% as compared to the same period in 2017 GAAP net income of $5.0 million and diluted GAAP earnings per share of $0.42 Adjusted non-GAAP E… read more...

Notable earnings before Tuesday's open

via: SeekingAlpha at 2018-11-05 17:30:09:000

AAC , ABC , ADM , AES , AFI , ANIP , APD , AVNS , BCC , BCPC , BDX , BHC , BIOS , BLD , BR , CORE , CTLT , CVS , ELAN , EMES , EMR , ETM , EXPD , FI , FRTA , FSS , GCP , GLDD , GLT , GOGO , GTN , GTX , HAE , HPT , HSIC , IONS , IRWD , JELD , JLL , KEYW… read more...

ANI Pharmaceuticals Schedules Conference Call to Discuss Third Quarter and Year-to-Date 2018 Financial Results

via: PR Newswire at 2018-10-30 08:30:00:000

BAUDETTE, Minn. , Oct. 30, 2018 /PRNewswire/ --ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its third quarter and year-to-date 2018 financial results on Tuesday, November 6, 2018 , before the opening of the U.S. financial markets. The e… read more...

ANI Pharmaceuticals Schedules Conference Call to Discuss Third Quarter and Year-to-Date 2018 Financial Results

via: PR Newswire at 2018-10-30 08:30:00:000

BAUDETTE, Minn. , Oct. 30, 2018 /PRNewswire/ --ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its third quarter and year-to-date 2018 financial results on Tuesday, November 6, 2018 , before the opening of the U.S. financial markets. The e… read more...

ANI Pharmaceuticals Schedules Conference Call to Discuss Third Quarter and Year-to-Date 2018 Financial Results

via: PR Newswire at 2018-10-30 08:30:00:000

BAUDETTE, Minn. , Oct. 30, 2018 /PRNewswire/ --ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its third quarter and year-to-date 2018 financial results on Tuesday, November 6, 2018 , before the opening of the U.S. financial markets. The e… read more...

ANI Announces Launch of Authorized Generic of Brethine®

via: PR Newswire at 2018-10-16 09:00:00:000

BAUDETTE, Minn. , Oct. 16, 2018 /PRNewswire/ --ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq:ANIP) today announced the launch of Terbutaline Sulfate Tablets USP, 2.5mg and 5mg, an authorized generic of Brethine.The current annual U.S. market for this product is approximately… read more...

ANI Announces Launch of Authorized Generic of Brethine®

via: PR Newswire at 2018-10-16 09:00:00:000

BAUDETTE, Minn. , Oct. 16, 2018 /PRNewswire/ --ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq:ANIP) today announced the launch of Terbutaline Sulfate Tablets USP, 2.5mg and 5mg, an authorized generic of Brethine.The current annual U.S. market for this product is approximately… read more...

ANI Announces Launch of Authorized Generic of Brethine®

via: PR Newswire at 2018-10-16 09:00:00:000

BAUDETTE, Minn. , Oct. 16, 2018 /PRNewswire/ --ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq:ANIP) today announced the launch of Terbutaline Sulfate Tablets USP, 2.5mg and 5mg, an authorized generic of Brethine.The current annual U.S. market for this product is approximately… read more...

ANI Pharmaceuticals launches authorized generic of Atacand HCT tablets

via: SeekingAlpha at 2018-10-04 09:24:10:000

ANI Pharmaceuticals (NASDAQ: ANIP ) launches Candesartan Hydrochlorothiazide Tablets, 16mg/12.5mg, 32mg/12.5mg, and 32mg/25mg, an authorized generic of Atacand HCT. More news on: ANI Pharmaceuticals, Inc., Healthcare stocks news, Read more … read more...

ANI Pharmaceuticals launches authorized generic of Atacand HCT tablets

via: SeekingAlpha at 2018-10-04 09:24:10:000

ANI Pharmaceuticals (NASDAQ: ANIP ) launches Candesartan Hydrochlorothiazide Tablets, 16mg/12.5mg, 32mg/12.5mg, and 32mg/25mg, an authorized generic of Atacand HCT. More news on: ANI Pharmaceuticals, Inc., Healthcare stocks news, Read more … read more...

ANI Pharmaceuticals launches authorized generic of Atacand HCT tablets

via: SeekingAlpha at 2018-10-04 09:24:10:000

ANI Pharmaceuticals (NASDAQ: ANIP ) launches Candesartan Hydrochlorothiazide Tablets, 16mg/12.5mg, 32mg/12.5mg, and 32mg/25mg, an authorized generic of Atacand HCT. More news on: ANI Pharmaceuticals, Inc., Healthcare stocks news, Read more … read more...

ANI Pharmaceuticals Announces Launch of Authorized Generic of Atacand HCT® Tablets

via: PR Newswire at 2018-10-04 08:30:00:000

BAUDETTE, Minn. , Oct. 4, 2018 /PRNewswire/ --ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the launch of Candesartan Hydrochlorothiazide Tablets, 16mg/12.5mg, 32mg/12.5mg, and 32mg/25mg, an authorized generic of Atacand HCT. The current annual U.S. ma… read more...

ANI Pharmaceuticals Announces Launch of Authorized Generic of Atacand HCT® Tablets

via: PR Newswire at 2018-10-04 08:30:00:000

BAUDETTE, Minn. , Oct. 4, 2018 /PRNewswire/ --ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the launch of Candesartan Hydrochlorothiazide Tablets, 16mg/12.5mg, 32mg/12.5mg, and 32mg/25mg, an authorized generic of Atacand HCT. The current annual U.S. ma… read more...

ANI Pharmaceuticals Announces Launch of Authorized Generic of Atacand HCT® Tablets

via: PR Newswire at 2018-10-04 08:30:00:000

BAUDETTE, Minn. , Oct. 4, 2018 /PRNewswire/ --ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the launch of Candesartan Hydrochlorothiazide Tablets, 16mg/12.5mg, 32mg/12.5mg, and 32mg/25mg, an authorized generic of Atacand HCT. The current annual U.S. ma… read more...

Generics in the green following proposed favorable guidance from FDA

via: SeekingAlpha at 2018-10-02 14:03:56:000

Most generic drug firms are enjoying an uptick in buying. This morning, FDA Commissioner Scott Gottlieb, M.D., released a statement on preliminary guidance aimed at making the review process for generic drug applications more efficient. More news on: Aceto Corporation, Aclaris Therapeutics… read more...

Generics in the green following proposed favorable guidance from FDA

via: SeekingAlpha at 2018-10-02 14:03:56:000

Most generic drug firms are enjoying an uptick in buying. This morning, FDA Commissioner Scott Gottlieb, M.D., released a statement on preliminary guidance aimed at making the review process for generic drug applications more efficient. More news on: Aceto Corporation, Aclaris Therapeutics… read more...

ANI Pharmaceuticals to Present at the Cantor Fitzgerald Global Healthcare Conference

via: PR Newswire at 2018-09-27 08:30:00:000

BAUDETTE, Minn. , Sept. 27, 2018 /PRNewswire/ --ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that it will present on Wednesday, October 3, 2018 at 2:50 PM ET at the Cantor Fitzgerald Global Healthcare Conference in New York City . Arthur S. Przybyl , President and … read more...

ANI Pharmaceuticals to Present at the Cantor Fitzgerald Global Healthcare Conference

via: PR Newswire at 2018-09-27 08:30:00:000

BAUDETTE, Minn. , Sept. 27, 2018 /PRNewswire/ --ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that it will present on Wednesday, October 3, 2018 at 2:50 PM ET at the Cantor Fitzgerald Global Healthcare Conference in New York City . Arthur S. Przybyl , President and … read more...

ANI Pharmaceuticals to Present at the Cantor Fitzgerald Global Healthcare Conference

via: PR Newswire at 2018-09-27 08:30:00:000

BAUDETTE, Minn. , Sept. 27, 2018 /PRNewswire/ --ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that it will present on Wednesday, October 3, 2018 at 2:50 PM ET at the Cantor Fitzgerald Global Healthcare Conference in New York City . Arthur S. Przybyl , President and … read more...

Investors shun healthcare stocks in broad market selloff

via: SeekingAlpha at 2018-08-15 10:14:45:000

Healthcare stocks are taking it on the chin in today's broad selloff, some more than others. The SPDR S&P Biotech ETF ( XBI -2% ), for example, is down more than the major indexes. More news on: SPDR Biotech ETF, Ionis Pharmaceuticals, Inc., Global Blood Therapeutics, Healthcare stoc… read more...

Investors shun healthcare stocks in broad market selloff

via: SeekingAlpha at 2018-08-15 10:14:45:000

Healthcare stocks are taking it on the chin in today's broad selloff, some more than others. The SPDR S&P Biotech ETF ( XBI -2% ), for example, is down more than the major indexes. More news on: SPDR Biotech ETF, Ionis Pharmaceuticals, Inc., Global Blood Therapeutics, Healthcare stoc… read more...

Investors shun healthcare stocks in broad market selloff

via: SeekingAlpha at 2018-08-15 10:14:45:000

Healthcare stocks are taking it on the chin in today's broad selloff, some more than others. The SPDR S&P Biotech ETF ( XBI -2% ), for example, is down more than the major indexes. More news on: SPDR Biotech ETF, Ionis Pharmaceuticals, Inc., Global Blood Therapeutics, Healthcare stoc… read more...

ANI Pharmaceuticals to Present at New Time at the Canaccord Genuity 38th Annual Growth Conference

via: PR Newswire at 2018-08-08 13:00:00:000

BAUDETTE, Minn. , Aug. 8, 2018 /PRNewswire/ --ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that, due to a scheduling change at Canaccord Genuity, ANI will now present on Thursday, August 9, 2018 at 2:00 PM ET at the Canaccord Genuity 38 th Annual Growth Conference. … read more...

ANI Pharmaceuticals to Present at New Time at the Canaccord Genuity 38th Annual Growth Conference

via: PR Newswire at 2018-08-08 13:00:00:000

BAUDETTE, Minn. , Aug. 8, 2018 /PRNewswire/ --ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that, due to a scheduling change at Canaccord Genuity, ANI will now present on Thursday, August 9, 2018 at 2:00 PM ET at the Canaccord Genuity 38 th Annual Growth Conference. … read more...

ANI Pharmaceuticals to Present at New Time at the Canaccord Genuity 38th Annual Growth Conference

via: PR Newswire at 2018-08-08 13:00:00:000

BAUDETTE, Minn. , Aug. 8, 2018 /PRNewswire/ --ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that, due to a scheduling change at Canaccord Genuity, ANI will now present on Thursday, August 9, 2018 at 2:00 PM ET at the Canaccord Genuity 38 th Annual Growth Conference. … read more...

Mylan's trimmed guidance may pressure generic drug makers

via: SeekingAlpha at 2018-08-08 09:07:22:000

Mylan (NASDAQ: MYL ) is under modest pressure premarket, down 5% on average volume, after cutting its 2018 guidance due to continued challenges in the U.S. market, a move that could stoke selling in the generics space. More news on: Mylan Inc, Teva Pharmaceutical Industries Lim… read more...

Mylan's trimmed guidance may pressure generic drug makers

via: SeekingAlpha at 2018-08-08 09:07:22:000

Mylan (NASDAQ: MYL ) is under modest pressure premarket, down 5% on average volume, after cutting its 2018 guidance due to continued challenges in the U.S. market, a move that could stoke selling in the generics space. More news on: Mylan Inc, Teva Pharmaceutical Industries Lim… read more...

Mylan's trimmed guidance may pressure generic drug makers

via: SeekingAlpha at 2018-08-08 09:07:22:000

Mylan (NASDAQ: MYL ) is under modest pressure premarket, down 5% on average volume, after cutting its 2018 guidance due to continued challenges in the U.S. market, a move that could stoke selling in the generics space. More news on: Mylan Inc, Teva Pharmaceutical Industries Lim… read more...

ANI Pharmaceuticals' (ANIP) CEO Arthur Przybyl on Q2 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-08-07 16:35:04:000

ANI Pharmaceuticals, Inc. (ANIP) Q2 2018 Earnings Conference Call August 7, 2018 10:30 AM ET Executives Arthur Przybyl Chief Executive Officer Stephen Carey Chief Financial Officer Analysts Dewey Steadman Canaccord Genuity Elliot Wilbur R… read more...

ANI Pharmaceuticals misses by $0.21, misses on revenue

via: SeekingAlpha at 2018-08-07 08:33:11:000

ANI Pharmaceuticals (NASDAQ: ANIP ): Q2 EPS of $1.13 misses by $0.21 . More news on: ANI Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...

ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2018 Results and Updates Guidance

via: PR Newswire at 2018-08-07 08:30:00:000

BAUDETTE, Minn. , Aug. 7, 2018 /PRNewswire/ -- For the second quarter 2018: Net revenues of $47.3 million , an increase of 6% as compared to the same period in 2017 GAAP net income of $2.8 million and diluted GAAP earnings per share of $0.23 Adjusted no… read more...

Notable earnings before Tuesday's open

via: SeekingAlpha at 2018-08-06 17:30:50:000

ACM , AES , AFI , AMRC , ANIP , AQUA , ARMK , ATKR , AVNS , AYR , BHC , BIOS , BLD , BOLD , BR , CEVA , CORE , CROX , DEA , DF , DISCA , DNR , DQ , EGN , EGRX , EMR , EPC , EXPD , FSS , GSKY , GTN , HAE , HLNE , IIVI , IONS , JELD , LABL , LGIH , LPX ,… read more...

ANI Pharmaceuticals to Present at the Canaccord Genuity 38th Annual Growth Conference

via: PR Newswire at 2018-08-06 08:30:00:000

BAUDETTE, Minn. , Aug. 6, 2018 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that it will present on Thursday, August 9, 2018 at 2:30 PM ET at the Canaccord Genuity 38 th Annual Growth Conference. Arthur S. Przybyl , President and CEO and Stephen P. Carey… read more...

ANI Pharmaceuticals Schedules Conference Call to Discuss Second Quarter and Year-to-Date 2018 Financial Results

via: PR Newswire at 2018-08-01 08:30:00:000

BAUDETTE, Minn. , Aug. 1, 2018 /PRNewswire/ --ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its second quarter and year-to-date 2018 financial results on Tuesday, August 7, 2018 , before the opening of the U.S. financial markets. The ear… read more...

ANI Pharmaceuticals Schedules Conference Call to Discuss Second Quarter and Year-to-Date 2018 Financial Results

via: PR Newswire at 2018-08-01 08:30:00:000

BAUDETTE, Minn. , Aug. 1, 2018 /PRNewswire/ --ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its second quarter and year-to-date 2018 financial results on Tuesday, August 7, 2018 , before the opening of the U.S. financial markets. The ear… read more...

ANI Pharmaceuticals Schedules Conference Call to Discuss Second Quarter and Year-to-Date 2018 Financial Results

via: PR Newswire at 2018-08-01 08:30:00:000

BAUDETTE, Minn. , Aug. 1, 2018 /PRNewswire/ --ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its second quarter and year-to-date 2018 financial results on Tuesday, August 7, 2018 , before the opening of the U.S. financial markets. The ear… read more...

ANI Pharmaceuticals Announces Launch of Cholestyramine for Oral Suspension USP

via: PR Newswire at 2018-06-27 08:00:00:000

BAUDETTE, Minn. , June 27, 2018 /PRNewswire/ --ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the launch of Cholestyramine for Oral Suspension USP, 4g/dose, in cans. The current annual U.S. market for this product is approximately $22 million , according to … read more...

ANI Pharmaceuticals Announces Launch of Cholestyramine for Oral Suspension USP

via: PR Newswire at 2018-06-27 08:00:00:000

BAUDETTE, Minn. , June 27, 2018 /PRNewswire/ --ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the launch of Cholestyramine for Oral Suspension USP, 4g/dose, in cans. The current annual U.S. market for this product is approximately $22 million , according to … read more...

ANI Pharmaceuticals Announces Launch of Cholestyramine for Oral Suspension USP

via: PR Newswire at 2018-06-27 08:00:00:000

BAUDETTE, Minn. , June 27, 2018 /PRNewswire/ --ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the launch of Cholestyramine for Oral Suspension USP, 4g/dose, in cans. The current annual U.S. market for this product is approximately $22 million , according to … read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-06-12 08:49:17:000

ANI Pharmaceuticals (NASDAQ: ANIP ) initiated with Overweight rating and $85 (28% upside) price target at Cantor Fitzgerald. More news on: ANI Pharmaceuticals, Inc., Biohaven Pharmaceutical Holding Company Ltd., Collegium Pharmaceutical, Healthcare stocks news, Stocks on the move, , Re… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-06-12 08:49:17:000

ANI Pharmaceuticals (NASDAQ: ANIP ) initiated with Overweight rating and $85 (28% upside) price target at Cantor Fitzgerald. More news on: ANI Pharmaceuticals, Inc., Biohaven Pharmaceutical Holding Company Ltd., Collegium Pharmaceutical, Healthcare stocks news, Stocks on the move, , Re… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-06-12 08:49:17:000

ANI Pharmaceuticals (NASDAQ: ANIP ) initiated with Overweight rating and $85 (28% upside) price target at Cantor Fitzgerald. More news on: ANI Pharmaceuticals, Inc., Biohaven Pharmaceutical Holding Company Ltd., Collegium Pharmaceutical, Healthcare stocks news, Stocks on the move, , Re… read more...

ANI Shareholders Elect Three New Members to the Board of Directors

via: PR Newswire at 2018-06-05 08:30:00:000

BAUDETTE, Minn. , June 5, 2018 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (NASDAQ: ANIP) today announced that the following three new members of the Board of Directors were elected at the Annual Meeting of Stockholders, held on May 17, 2018 : Thomas J. Haughey held the role … read more...

ANI Shareholders Elect Three New Members to the Board of Directors

via: PR Newswire at 2018-06-05 08:30:00:000

BAUDETTE, Minn. , June 5, 2018 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (NASDAQ: ANIP) today announced that the following three new members of the Board of Directors were elected at the Annual Meeting of Stockholders, held on May 17, 2018 : Thomas J. Haughey held the role … read more...

ANI Shareholders Elect Three New Members to the Board of Directors

via: PR Newswire at 2018-06-05 08:30:00:000

BAUDETTE, Minn. , June 5, 2018 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (NASDAQ: ANIP) today announced that the following three new members of the Board of Directors were elected at the Annual Meeting of Stockholders, held on May 17, 2018 : Thomas J. Haughey held the role … read more...

ANI Pharmaceuticals' (ANIP) CEO Arthur Przybyl on Q1 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-05-08 21:07:08:000

ANI Pharmaceuticals, Inc. (ANIP) Q1 2018 Earnings Conference Call May 08, 2018 10:30 AM ET Executives Arthur Przybyl - CEO, President and Director Stephen Carey - CFO and VP of Finance Analysts Dewey Steadman - Canaccord Elliot Wilbur - Raymond James Presentation Ope… read more...

ANI Pharmaceuticals' (ANIP) CEO Arthur Przybyl on Q1 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-05-08 21:07:08:000

ANI Pharmaceuticals, Inc. (ANIP) Q1 2018 Earnings Conference Call May 08, 2018 10:30 AM ET Executives Arthur Przybyl - CEO, President and Director Stephen Carey - CFO and VP of Finance Analysts Dewey Steadman - Canaccord Elliot Wilbur - Raymond James Presentation Ope… read more...

ANI Pharmaceuticals beats by $0.04, misses on revenue

via: SeekingAlpha at 2018-05-08 08:33:10:000

ANI Pharmaceuticals (NASDAQ: ANIP ): Q1 EPS of $1.32 beats by $0.04 . Revenue of $46.5M (+26.9% Y/Y) misses by $3.43M . Press Release More news on: ANI Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, read more...

ANI Pharmaceuticals beats by $0.04, misses on revenue

via: SeekingAlpha at 2018-05-08 08:33:10:000

ANI Pharmaceuticals (NASDAQ: ANIP ): Q1 EPS of $1.32 beats by $0.04 . Revenue of $46.5M (+26.9% Y/Y) misses by $3.43M . Press Release More news on: ANI Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, read more...

ANI Pharmaceuticals Reports First Quarter 2018 Results and Reaffirms Guidance

via: PR Newswire at 2018-05-08 08:30:00:000

BAUDETTE, Minn. , May 8, 2018 /PRNewswire/ -- For the first quarter 2018: Net revenues of $46.5 million , an increase of 27% as compared to the same period in 2017 GAAP net income of $2.3 million and diluted GAAP earnings per share of $0.19 Adjusted non-GAAP EBITDA … read more...

ANI Pharmaceuticals Reports First Quarter 2018 Results and Reaffirms Guidance

via: PR Newswire at 2018-05-08 08:30:00:000

BAUDETTE, Minn. , May 8, 2018 /PRNewswire/ -- For the first quarter 2018: Net revenues of $46.5 million , an increase of 27% as compared to the same period in 2017 GAAP net income of $2.3 million and diluted GAAP earnings per share of $0.19 Adjusted non-GAAP EBITDA … read more...

Notable earnings before Tuesday's open

via: SeekingAlpha at 2018-05-07 17:30:20:000

ACM , AES , AFI , ANIP , AQUA , ARMK , ATHM , ATRS , BLD , BMCH , BR , COHU , CORE , CRCM , CROX , CWH , DEA , DF , DISCA , DISH , DNR , DQ , EGN , ENDP , EPZM , ETM , EXPD , FI , FRTA , FSS , GCP , GTN , HAE , HAIN , HSIC , HUD , ICPT , IT , JD , JEC… read more...

Notable earnings before Tuesday's open

via: SeekingAlpha at 2018-05-07 17:30:20:000

ACM , AES , AFI , ANIP , AQUA , ARMK , ATHM , ATRS , BLD , BMCH , BR , COHU , CORE , CRCM , CROX , CWH , DEA , DF , DISCA , DISH , DNR , DQ , EGN , ENDP , EPZM , ETM , EXPD , FI , FRTA , FSS , GCP , GTN , HAE , HAIN , HSIC , HUD , ICPT , IT , JD , JEC… read more...

ANI Pharmaceuticals Completes Acquisition of Generic Products and Assets from Amneal/Impax

via: PR Newswire at 2018-05-07 08:30:00:000

BAUDETTE, Minn. , May 7, 2018 /PRNewswire/ --ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced that it has completed the acquisition of a portfolio of six generic products, related manufacturing and supply agreements, and equipment and technical know-how from Amneal P… read more...

ANI Pharmaceuticals Completes Acquisition of Generic Products and Assets from Amneal/Impax

via: PR Newswire at 2018-05-07 08:30:00:000

BAUDETTE, Minn. , May 7, 2018 /PRNewswire/ --ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced that it has completed the acquisition of a portfolio of six generic products, related manufacturing and supply agreements, and equipment and technical know-how from Amneal P… read more...

ANI Pharmaceuticals Schedules Conference Call to Discuss First Quarter 2018 Financial Results

via: PR Newswire at 2018-05-01 08:30:00:000

BAUDETTE, Minn. , May 1, 2018 /PRNewswire/ --ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its first quarter 2018 financial results on Tuesday, May 8, 2018 , before the opening of the U.S. financial markets. The earnings press release… read more...

ANI Pharmaceuticals Schedules Conference Call to Discuss First Quarter 2018 Financial Results

via: PR Newswire at 2018-05-01 08:30:00:000

BAUDETTE, Minn. , May 1, 2018 /PRNewswire/ --ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its first quarter 2018 financial results on Tuesday, May 8, 2018 , before the opening of the U.S. financial markets. The earnings press release… read more...

Your Daily Pharma Scoop: Akorn Revives, Eloxx Secondary, Celyad Moves Up

via: SeekingAlpha at 2018-04-30 08:00:00:000

Analysis focus: Akorn Akorn Therapeutics (AKRX) has gained considerably on hopes that it will, after all, reach a buyout deal with Fresenius (FMS). The $4.75bn deal has been going through some rough patch after Fresenius pulled out of the deal last week. Trouble began in late February wh… read more...

Your Daily Pharma Scoop: Akorn Revives, Eloxx Secondary, Celyad Moves Up

via: SeekingAlpha at 2018-04-30 08:00:00:000

Analysis focus: Akorn Akorn Therapeutics (AKRX) has gained considerably on hopes that it will, after all, reach a buyout deal with Fresenius (FMS). The $4.75bn deal has been going through some rough patch after Fresenius pulled out of the deal last week. Trouble began in late February wh… read more...

ANI Pharmaceuticals buying assets from Amneal, Impax

via: SeekingAlpha at 2018-04-27 19:13:24:000

ANI Pharmaceuticals (NASDAQ: ANIP ) has signed definitive deals to acquire generic products and assets from Amneal Pharmaceuticals and Impax Laboratories (NASDAQ: IPXL ) for cash. More news on: ANI Pharmaceuticals, Inc., Impax Laboratories, Inc., Healthcare stocks news, Merger & acqu… read more...

ANI Pharmaceuticals buying assets from Amneal, Impax

via: SeekingAlpha at 2018-04-27 19:13:24:000

ANI Pharmaceuticals (NASDAQ: ANIP ) has signed definitive deals to acquire generic products and assets from Amneal Pharmaceuticals and Impax Laboratories (NASDAQ: IPXL ) for cash. More news on: ANI Pharmaceuticals, Inc., Impax Laboratories, Inc., Healthcare stocks news, Merger & acqu… read more...

Amneal And Impax Receive FTC Clearance For Business Combination

via: PR Newswire at 2018-04-27 18:50:00:000

BRIDGEWATER, N.J. , April 27, 2018 /PRNewswire/ -- Amneal Pharmaceuticals LLC and Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the U.S. Federal Trade Commission (FTC) has cleared the Amneal and Impax business combination, subject to Amneal and Impax's agreement to… read more...

Amneal And Impax Receive FTC Clearance For Business Combination

via: PR Newswire at 2018-04-27 18:50:00:000

BRIDGEWATER, N.J. , April 27, 2018 /PRNewswire/ -- Amneal Pharmaceuticals LLC and Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the U.S. Federal Trade Commission (FTC) has cleared the Amneal and Impax business combination, subject to Amneal and Impax's agreement to… read more...

ANI Pharmaceuticals Signs Definitive Agreements to Acquire Generic Products and Assets from Amneal/Impax

via: PR Newswire at 2018-04-27 18:30:00:000

BAUDETTE, Minn. , April 27, 2018 /PRNewswire/ --ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced that it has signed definitive agreements to acquire a portfolio of generic products and other assets from Amneal Pharmaceuticals, LLC and Impax Laboratories, Inc. (NASDAQ… read more...

ANI Pharmaceuticals Signs Definitive Agreements to Acquire Generic Products and Assets from Amneal/Impax

via: PR Newswire at 2018-04-27 18:30:00:000

BAUDETTE, Minn. , April 27, 2018 /PRNewswire/ --ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced that it has signed definitive agreements to acquire a portfolio of generic products and other assets from Amneal Pharmaceuticals, LLC and Impax Laboratories, Inc. (NASDAQ… read more...

U.S. Justice Department may seek damages from generic drugmakers for price-fixing

via: SeekingAlpha at 2018-01-19 13:16:00:000

Some generic drug firms are under modest pressure in apparent response to a speech delivered by U.S. Department of Justice antitrust division chief Makan Delrahim earlier today at George Mason University's law school. He said the DOJ may sue generic drug companies to recover damages over all… read more...

Wall Street Breakfast: Investors Calm As Government Shutdown Looms

via: SeekingAlpha at 2018-01-19 07:01:29:000

Markets appear to be shrugging off the potential for a government shutdown as traders are reminded that nearly $6.9T has been added to the U.S. stock market cap over the last year (President Trump will celebrate his inauguration anniversary tomorrow). Though House Republicans have v… read more...

Generic firms under pressure on possible hospital drug-making venture

via: SeekingAlpha at 2018-01-18 10:06:04:000

Generic drug makers are under pressure in early trading on the heels of a New York Times article about hospital groups' plans to establish a non-profit drug company aimed at supplying certain generic drugs at affordable prices. More news on: Amphastar, ANI Pharmaceuticals, Inc., Aclaris Th… read more...

Hospital groups planning to enter generic drugs business

via: SeekingAlpha at 2018-01-18 08:21:15:000

The NYT reports that some U.S. hospital systems are planning to enter the generic drugs business in an effort to preserve the supply of key off-patent medicines at affordable prices. About 300 hospitals, led by Utah-based Intermountain Healthcare, are on board with more to follow. More n… read more...

Biotech Forum Daily Digest: A Volatile Opening To 2018

via: SeekingAlpha at 2018-01-04 11:33:07:000

I am fond of pigs. Dogs look up to us. Cats look down on us. Pigs treat us as equals . Winston S. Churchill The biotech sector opened with a bang here in 2018. Solid rallies Tuesday and Wednesday were followed by a quick reversal this morning. After opening up, it seemed … read more...

FDA advancing plan to streamline generic drug reviews

via: SeekingAlpha at 2018-01-03 12:54:23:000

The FDA released two documents today aimed at making the generic drug application and review process more efficient, the aim of its Drug Competition Action Plan. More news on: Amphastar, ANI Pharmaceuticals, Inc., Aclaris Therapeutics, Healthcare stocks news, News on ETFs, Read more … read more...

Your Daily Pharma Scoop: Progenics Azerda Update, Atara Gets FDA Clearance For Phase 3 Trial, Avadel Provides Update

via: SeekingAlpha at 2017-12-31 09:42:35:000

Analysis of top Seeking Alpha coverage: Progenics Today we will discuss the latest update from Progenics Pharmaceuticals ( PGNX ), which sparked a rally in pre-market trading on Friday . Progenics announced that the FDA has accepted for review its New Drug Application (NDA) for Azed… read more...

ANI Pharmaceuticals acquires four AstraZeneca NDAs

via: SeekingAlpha at 2017-12-29 11:57:57:000

ANI Pharmaceuticals (NASDAQ: ANIP ) acquires the NDAs and U.S. marketing rights for AstraZenecas Atacand (hypertension), Atacand HCT, Arimidex (breast cancer), and Casodex (prostate cancer). More news on: ANI Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, … read more...

ANI Pharmaceuticals Enters Five-Year $125 Million Senior Secured Credit Facility with Citizens Bank

via: PR Newswire at 2017-12-29 09:26:00:000

BAUDETTE, Minn. , Dec. 29, 2017 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced that it has entered a new five-year Senior Secured Credit Facility (the "Facility") for up to $125 million with Citizens Bank. The Facility is comprised of a $75 million fi… read more...

ANI Pharmaceuticals Acquires Four NDAs from AstraZeneca for $46.5 Million

via: PR Newswire at 2017-12-29 09:21:00:000

BAUDETTE, Minn. , Dec. 29, 2017 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced that it has acquired the NDAs and U.S. rights to market ATACAND, ATACAND HCT, ARIMIDEX, and CASODEX from AstraZeneca for $46.5 million in cash, royalt… read more...

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
2013-07-18 6.0 1.0 6.0
Data provided for free by IEX